Moderna Inc. (NASDAQ:MRNA) is one of the best high volume stocks to buy according to Wall Street analysts. On October 13, ...

CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, ...

Moderna's Phase 1/2 study shows mRNA-4359 plus pembrolizumab yields 24% response rate and 60% disease control in resistant ...

CAMBRIDGE, MA / ACCESS Newswire / October 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 6, 2025 to ...

Moderna, Inc. (NASDAQ:MRNA) ranks among the best biotech stocks to buy. Following solid trial results for Moderna, Inc. (NASDAQ:MRNA)’s refrigerator-stable COVID-19 vaccine, Brookline Capital Markets ...

Moderna faces significant uncertainty ahead of Q3 earnings, with heavy reliance on COVID vaccine revenues and limited ...

mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older ...

RNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial CAMBRIDGE, MA / ACCESS Newswire / October 12, ...

Moderna is producing its first made-in-Canada COVID-19 shots at facilities in Laval, Que. and Cambridge, Ont. The Laval ...

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groupsClinical findings reinforce preclinical data ...

We recently published a list of Billionaire David E. Shaw’s 10 Small-Cap Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) ...